Genmab A/S (GNMSF)
OTCMKTS
· Delayed Price · Currency is USD
221.77
-18.23 (-7.60%)
Mar 10, 2025, 10:53 AM EST
Genmab Revenue
In the year 2024, Genmab had annual revenue of 21.53B DKK with 30.67% growth. Genmab had revenue of 6.44B in the quarter ending December 31, 2024, with 35.34% growth.
Revenue
21.53B DKK
Revenue Growth
+30.67%
P/S Ratio
n/a
Revenue / Employee
8.03M DKK
Employees
2,682
Market Cap
12.86B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| BioStem Technologies | 210.49M |
Genmab News
- 7 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 11 days ago - Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - GlobeNewsWire
- 14 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 20 days ago - EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 21 days ago - Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 22 days ago - Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon - Seeking Alpha
- 26 days ago - Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 26 days ago - Genmab A/S 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha